Reduction of dialyzer fibrin deposition with sulphinpyrazone.
To determine whether sulphinpyrazone reduces thrombus formation within artificial kidneys, dialyzer 125I-fibrinogen and platelet and fibrinogen levels during dialysis were compared during a non-treatment control period and while patients were receiving sulphinpyrazone. Mean fibrin deposition within the dialyzers, measured as gram X 10(-3) of clottable fibrinogen, was significantly less during sulphinpyrazone treatment (2.5) than during the control period (5.3). Arterial blood platelet counts and plasma fibrinogen levels during dialysis were higher on treatment despite similar predialysis values during control and treatment periods. The results indicate that sulphinpyrazone reduces fibrin formation within artificial kidneys and, since the reduction in deposition of fibrin alone is insufficient to explain the higher plasma fibrinogen levels during treatment with sulphinpyrazone, suggests that this therapy reduces fibrinogen consumption within the patient during hemodialysis.
D001792:Blood Platelets; D005337:Fibrin / Q000032:analysis*; D005340:Fibrinogen / Q000097:blood; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy*; D007688:Kidneys, Artificial; D013442:Sulfinpyrazone / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000517:prevention & control
D005337:Fibrin; D005340:Fibrinogen; D013442:Sulfinpyrazone